These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31259884)

  • 1. Linezolid Dosing in Patients With Liver Cirrhosis: Standard Dosing Risk Toxicity.
    Luque S; Muñoz-Bermudez R; Echeverría-Esnal D; Sorli L; Campillo N; Martínez-Casanova J; González-Colominas E; Álvarez-Lerma F; Horcajada JP; Grau S; Roberts JA
    Ther Drug Monit; 2019 Dec; 41(6):732-739. PubMed ID: 31259884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?
    Pea F; Cojutti PG; Baraldo M
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):303-308. PubMed ID: 28419737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.
    Kawasuji H; Tsuji Y; Ogami C; Kimoto K; Ueno A; Miyajima Y; Kawago K; Sakamaki I; Yamamoto Y
    BMC Pharmacol Toxicol; 2021 Mar; 22(1):13. PubMed ID: 33663616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors associated with high linezolid trough plasma concentrations.
    Morata L; De la Calle C; Gómez-Cerquera JM; Manzanedo L; Casals G; Brunet M; Cobos-Trigueros N; Martínez JA; Mensa J; Soriano A
    Expert Opin Pharmacother; 2016 Jun; 17(9):1183-7. PubMed ID: 27156708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety.
    Crass RL; Cojutti PG; Pai MP; Pea F
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linezolid in liver failure: exploring the value of the maximal liver function capacity (LiMAx) test in a pharmacokinetic pilot study.
    Wicha SG; Frey OR; Roehr AC; Pratschke J; Stockmann M; Alraish R; Wuensch T; Kaffarnik M
    Int J Antimicrob Agents; 2017 Oct; 50(4):557-563. PubMed ID: 28711678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early linezolid-associated lactic acidosis in a patient with Child's class C liver cirrhosis and end stage renal disease.
    Cheng CN; Lin SW; Wu CC
    J Infect Chemother; 2018 Oct; 24(10):841-844. PubMed ID: 29503228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.
    Cojutti P; Pai MP; Pea F
    Clin Pharmacokinet; 2018 Aug; 57(8):989-1000. PubMed ID: 29080937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosage regimen and toxicity risk assessment of linezolid in sepsis patients.
    Dou L; Meng D; Dong Y; Chen L; Han X; Fan D; Dong H
    Int J Infect Dis; 2020 Jul; 96():105-111. PubMed ID: 32251797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics.
    Rao GG; Konicki R; Cattaneo D; Alffenaar JW; Marriott DJE; Neely M;
    Ther Drug Monit; 2020 Feb; 42(1):83-92. PubMed ID: 31652190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug management of linezolid: a missed opportunity for clinicians?
    Cattaneo D; Gervasoni C; Cozzi V; Castoldi S; Baldelli S; Clementi E
    Int J Antimicrob Agents; 2016 Dec; 48(6):728-731. PubMed ID: 27769709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and preliminary safety of high dose linezolid for the treatment of Gram-positive bacterial infections.
    Lopez-Garcia B; Luque S; Roberts JA; Grau S
    J Infect; 2015 Nov; 71(5):604-7. PubMed ID: 26099449
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients.
    Dong H; Xie J; Wang T; Chen L; Zeng X; Sun J; Wang X; Dong Y
    Int J Antimicrob Agents; 2016 Sep; 48(3):259-64. PubMed ID: 27474469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of linezolid in critically ill patients.
    Sazdanovic P; Jankovic SM; Kostic M; Dimitrijevic A; Stefanovic S
    Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):595-600. PubMed ID: 27020789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy.
    Ide T; Takesue Y; Ikawa K; Morikawa N; Ueda T; Takahashi Y; Nakajima K; Takeda K; Nishi S
    Int J Antimicrob Agents; 2018 May; 51(5):745-751. PubMed ID: 29425834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variable Linezolid Exposure in Intensive Care Unit Patients-Possible Role of Drug-Drug Interactions.
    Töpper C; Steinbach CL; Dorn C; Kratzer A; Wicha SG; Schleibinger M; Liebchen U; Kees F; Salzberger B; Kees MG
    Ther Drug Monit; 2016 Oct; 38(5):573-8. PubMed ID: 27631464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.
    Wasserman S; Meintjes G; Maartens G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):901-15. PubMed ID: 27532292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, toxicity and clinical efficacy of linezolid in Japanese pediatric patients.
    Ogami C; Tsuji Y; To H; Yamamoto Y
    J Infect Chemother; 2019 Dec; 25(12):979-986. PubMed ID: 31208925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics and Dosing Optimization of Linezolid in Pediatric Patients.
    Li SC; Ye Q; Xu H; Zhang L; Wang Y
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30642929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the haematological profile of 21 days of tedizolid in healthy subjects.
    Lodise TP; Bidell MR; Flanagan SD; Zasowski EJ; Minassian SL; Prokocimer P
    J Antimicrob Chemother; 2016 Sep; 71(9):2553-8. PubMed ID: 27317442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.